Home LiteratureArticle Details
PMID: 21304480 Published · ppublish English Journal Article Review

Epidemiology of Alzheimer disease.

Nature reviews. Neurology ·Vol. 7 ·No. 3 ·2011-03-00 ·Pages 137-52

Reitz C, Brayne C, Mayeux R

Abstract

The global prevalence of dementia is estimated to be as high as 24 million, and is predicted to double every 20 years through to 2040, leading to a costly burden of disease. Alzheimer disease (AD) is the leading cause of dementia and is characterized by a progressive decline in cognitive function, which typically begins with deterioration in memory. Before death, individuals with this disorder have usually become dependent on caregivers. The neuropathological hallmarks of the AD brain are diffuse and neuritic extracellular amyloid plaques-which are frequently surrounded by dystrophic neurites-and intracellular neurofibrillary tangles. These hallmark pathologies are often accompanied by the presence of reactive microgliosis and the loss of neurons, white matter and synapses. The etiological mechanisms underlying the neuropathological changes in AD remain unclear, but are probably affected by both environmental and genetic factors. Here, we provide an overview of the criteria used in the diagnosis of AD, highlighting how this disease is related to, but distinct from, normal aging. We also summarize current information relating to AD prevalence, incidence and risk factors, and review the biomarkers that may be used for risk assessment and in diagnosis.

MeSH Terms
Alzheimer Disease/diagnostic imaging,epidemiology,metabolism,pathology Biomarkers/metabolism Comorbidity Global Health Humans Hypertension/epidemiology,pathology Prevalence Radiography Risk Factors
Chemicals
Biomarkers
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Reitz Christiane
Gertrude H. Sergievsky Center, Columbia University Medical Center, 630 West 168th Street, New York, NY 10032, USA.
Brayne Carol
Mayeux Richard
References (202)
202 references, click to expand
  1. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease.
    Brain. 2006 Nov;129(Pt 11):3035-41 PMID: 17012293
  2. Cholesterol paradox: is high total or low HDL cholesterol level a risk for Alzheimer's disease?
    J Neurosci Res. 2003 Apr 15;72(2):141-6 PMID: 12671988
  3. Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease.
    Lancet Neurol. 2005 Nov;4(11):705-11 PMID: 16239176
  4. Apolipoprotein E4 influences amyloid deposition but not cell loss after traumatic brain injury in a mouse model of Alzheimer's disease.
    J Neurosci. 2002 Dec 1;22(23):10083-7 PMID: 12451108
  5. Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease.
    Am J Hum Genet. 2009 Jan;84(1):35-43 PMID: 19118814
  6. Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging.
    JAMA. 2009 Dec 16;302(23):2565-72 PMID: 20009056
  7. Vitamin E and donepezil for the treatment of mild cognitive impairment.
    N Engl J Med. 2005 Jun 9;352(23):2379-88 PMID: 15829527
  8. Leptin and its role in hippocampal synaptic plasticity.
    Prog Lipid Res. 2006 Sep;45(5):369-78 PMID: 16678906
  9. Midlife vascular risk factors and late-life mild cognitive impairment: A population-based study.
    Neurology. 2001 Jun 26;56(12):1683-9 PMID: 11425934
  10. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.
    N Engl J Med. 1997 Apr 24;336(17):1216-22 PMID: 9110909
  11. Alzheimer's disease after remote head injury: an incidence study.
    J Neurol Neurosurg Psychiatry. 1997 Feb;62(2):119-24 PMID: 9048710
  12. Inhibition of CDK5 is protective in necrotic and apoptotic paradigms of neuronal cell death and prevents mitochondrial dysfunction.
    Mol Cell Neurosci. 2003 Oct;24(2):489-502 PMID: 14572469
  13. Association between high-density lipoprotein and cognitive impairment in the oldest old.
    Ann Neurol. 2002 Jun;51(6):716-21 PMID: 12112077
  14. Impact of depressive symptoms on the rate of progression to dementia in patients affected by mild cognitive impairment. The Italian Longitudinal Study on Aging.
    Int J Geriatr Psychiatry. 2008 Jul;23(7):726-34 PMID: 18188869
  15. Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging.
    J Alzheimers Dis. 2010;20(4):1233-42 PMID: 20413897
  16. Functional MR imaging in Alzheimer's disease during memory encoding.
    AJNR Am J Neuroradiol. 2000 Nov-Dec;21(10):1869-75 PMID: 11110539
  17. Adiposity indicators and dementia over 32 years in Sweden.
    Neurology. 2009 Nov 10;73(19):1559-66 PMID: 19901247
  18. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease.
    Pharmacogenomics J. 2006 Jul-Aug;6(4):246-54 PMID: 16446752
  19. Physical activity and enhanced fitness to improve cognitive function in older people without known cognitive impairment.
    Cochrane Database Syst Rev. 2008 Jul 16;(3):CD005381 PMID: 18646126
  20. Are tobacco and alcohol use related to Alzheimer's disease? A critical assessment of the evidence and its implications.
    Addict Biol. 1996;1(3):237-54 PMID: 12893463
  21. Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps.
    Arch Neurol. 2006 May;63(5):693-9 PMID: 16682538
  22. MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption.
    Cell. 1997 Apr 18;89(2):297-308 PMID: 9108484
  23. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial.
    Ann Neurol. 2002 Sep;52(3):346-50 PMID: 12205648
  24. Relation of smoking and alcohol consumption to incident Alzheimer's disease.
    Am J Epidemiol. 1992 Feb 15;135(4):347-55 PMID: 1550089
  25. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial.
    JAMA. 2008 Sep 3;300(9):1027-37 PMID: 18768414
  26. Head trauma and risk of dementia and Alzheimer's disease: The Rotterdam Study.
    Neurology. 1999 Dec 10;53(9):1959-62 PMID: 10599765
  27. Walking and dementia in physically capable elderly men.
    JAMA. 2004 Sep 22;292(12):1447-53 PMID: 15383515
  28. Midlife cardiovascular risk factors and risk of dementia in late life.
    Neurology. 2005 Jan 25;64(2):277-81 PMID: 15668425
  29. Neurobiology of exercise.
    Obesity (Silver Spring). 2006 Mar;14(3):345-56 PMID: 16648603
  30. Alcohol consumption as a risk factor for dementia and cognitive decline: meta-analysis of prospective studies.
    Am J Geriatr Psychiatry. 2009 Jul;17(7):542-55 PMID: 19546653
  31. Vitamin E and neurodegenerative disorders associated with oxidative stress.
    Nutr Neurosci. 2002 Sep;5(4):229-39 PMID: 12168685
  32. Dietary intake of antioxidants and risk of Alzheimer disease.
    JAMA. 2002 Jun 26;287(24):3223-9 PMID: 12076218
  33. Apolipoprotein E polymorphism and Alzheimer's disease.
    Lancet. 1993 Sep 18;342(8873):697-9 PMID: 8103819
  34. Dietary intake of unsaturated fatty acids and age-related cognitive decline: a 8.5-year follow-up of the Italian Longitudinal Study on Aging.
    Neurobiol Aging. 2006 Nov;27(11):1694-704 PMID: 16256248
  35. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease.
    Nat Genet. 2009 Oct;41(10):1088-93 PMID: 19734902
  36. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment.
    Dement Geriatr Cogn Disord. 2007;23(5):316-20 PMID: 17374949
  37. Mediterranean diet and mild cognitive impairment.
    Arch Neurol. 2009 Feb;66(2):216-25 PMID: 19204158
  38. Association of vitamin E and C supplement use with cognitive function and dementia in elderly men.
    Neurology. 2000 Mar 28;54(6):1265-72 PMID: 10746596
  39. The relationship of hypertension in the elderly to AD, vascular dementia, and cognitive function.
    Neurology. 2002 Apr 23;58(8):1175-81 PMID: 11971083
  40. Obesity in middle age and future risk of dementia: midlife obesity increases risk of future dementia.
    BMJ. 2005 Aug 20;331(7514):455; author reply 455 PMID: 16110085
  41. The association of weight change in Alzheimer's disease with severity of disease and mortality: a longitudinal analysis.
    J Am Geriatr Soc. 1998 Oct;46(10):1223-7 PMID: 9777903
  42. Diabetes-associated SorCS1 regulates Alzheimer's amyloid-beta metabolism: evidence for involvement of SorL1 and the retromer complex.
    J Neurosci. 2010 Sep 29;30(39):13110-5 PMID: 20881129
  43. Current status of antioxidant therapy for Alzheimer's Disease.
    J Am Geriatr Soc. 1998 Dec;46(12):1566-72 PMID: 9848820
  44. Polyunsaturated fatty acids, inflammation, and immunity.
    Lipids. 2001 Sep;36(9):1007-24 PMID: 11724453
  45. Diet and risk of dementia: Does fat matter?: The Rotterdam Study.
    Neurology. 2002 Dec 24;59(12):1915-21 PMID: 12499483
  46. Low body weight in Alzheimer's disease is associated with mesial temporal cortex atrophy.
    Neurology. 1996 Jun;46(6):1585-91 PMID: 8649553
  47. Volumes of medial temporal lobe structures in patients with Alzheimer's disease and mild cognitive impairment (and in healthy controls).
    Biol Psychiatry. 1998 Jan 1;43(1):60-8 PMID: 9442345
  48. Systolic blood pressure tracking over 25 to 30 years and cognitive performance in older adults.
    Stroke. 1998 Nov;29(11):2334-40 PMID: 9804644
  49. Association of depression with subsequent mortality, cardiovascular morbidity and incident dementia in people aged 80 and over and suffering from hypertension. Data from the Hypertension in the Very Elderly Trial (HYVET).
    Age Ageing. 2010 Jul;39(4):439-45 PMID: 20497949
  50. Clinical and epidemiological aspects of Alzheimer's disease with presenile onset: a case control study.
    Neuroepidemiology. 1990;9(1):39-49 PMID: 2330070
  51. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.
    Ann Neurol. 2006 Mar;59(3):512-9 PMID: 16372280
  52. Levels of ApoE in cerebrospinal fluid are correlated with Tau and 24S-hydroxycholesterol in patients with cognitive disorders.
    Neurosci Lett. 2007 Sep 25;425(2):78-82 PMID: 17822846
  53. High-density lipoprotein cholesterol in differential diagnosis of senile dementia.
    Lancet. 1985 May 25;1(8439):1191-3 PMID: 2860390
  54. Metabolic syndrome and risk for incident Alzheimer's disease or vascular dementia: the Three-City Study.
    Diabetes Care. 2009 Jan;32(1):169-74 PMID: 18945929
  55. Differential association of [11C]PIB and [18F]FDDNP binding with cognitive impairment.
    Neurology. 2009 Dec 15;73(24):2079-85 PMID: 20018636
  56. Elevated serum total and LDL cholesterol in very old patients with Alzheimer's disease.
    Dement Geriatr Cogn Disord. 2001 Mar-Apr;12(2):138-45 PMID: 11173887
  57. The number of trait loci in late-onset Alzheimer disease.
    Am J Hum Genet. 2000 Jan;66(1):196-204 PMID: 10631151
  58. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study.
    Lancet Neurol. 2006 Aug;5(8):655-60 PMID: 16857570
  59. The risk of dementia among persons with diabetes mellitus: a population-based cohort study.
    Ann N Y Acad Sci. 1997 Sep 26;826:422-7 PMID: 9329716
  60. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study.
    Arch Neurol. 2006 Nov;63(11):1545-50 PMID: 17101822
  61. Relationship between cigarette smoking and Alzheimer's disease in a population-based case-control study.
    Neurology. 1993 Feb;43(2):293-300 PMID: 8437692
  62. Increased risk of type 2 diabetes in Alzheimer disease.
    Diabetes. 2004 Feb;53(2):474-81 PMID: 14747300
  63. Chronic psychosocial stress-induced impairment of hippocampal LTP: possible role of BDNF.
    Neurobiol Dis. 2006 Jun;22(3):453-62 PMID: 16530419
  64. Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment.
    Curr Alzheimer Res. 2007 Apr;4(2):147-52 PMID: 17430239
  65. The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications.
    CNS Drugs. 2008;22(1):1-14 PMID: 18072811
  66. Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders.
    Biol Psychiatry. 2010 Mar 15;67(6):505-12 PMID: 19358976
  67. Benefits of fatty fish on dementia risk are stronger for those without APOE epsilon4.
    Neurology. 2005 Nov 8;65(9):1409-14 PMID: 16275829
  68. RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier.
    Stroke. 2004 Nov;35(11 Suppl 1):2628-31 PMID: 15459432
  69. The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta42(43).
    Neurology. 1997 Mar;48(3):741-5 PMID: 9065558
  70. Head injury as a risk factor in Alzheimer's disease.
    Brain Inj. 1995 Apr;9(3):213-9 PMID: 7606235
  71. Vitamin C and prevention of nitrosamine formation.
    Lancet. 1977 Sep 17;2(8038):607 PMID: 71419
  72. Comparative proteomic analysis of brains of naturally aging mice.
    Neuroscience. 2008 Jun 26;154(3):1107-20 PMID: 18495355
  73. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study.
    JAMA. 2002 Jun 26;287(24):3230-7 PMID: 12076219
  74. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.
    Science. 1993 Aug 13;261(5123):921-3 PMID: 8346443
  75. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis.
    Lancet Neurol. 2009 Nov;8(11):1006-18 PMID: 19782001
  76. The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study.
    JAMA. 1995 Dec 20;274(23):1846-51 PMID: 7500533
  77. Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease.
    Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):14052-7 PMID: 18779561
  78. Elevated low-density lipoprotein in Alzheimer's disease correlates with brain abeta 1-42 levels.
    Biochem Biophys Res Commun. 1998 Nov 27;252(3):711-5 PMID: 9837771
  79. Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele.
    Am J Pathol. 2003 Jan;162(1):313-9 PMID: 12507914
  80. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype.
    Neurobiol Aging. 2006 Mar;27(3):451-8 PMID: 15964100
  81. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels.
    Arch Neurol. 2003 Jul;60(7):958-64 PMID: 12873852
  82. Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults.
    BMJ. 1996 Mar 30;312(7034):801-5 PMID: 8608285
  83. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
    JAMA. 1991 Jun 26;265(24):3255-64 PMID: 2046107
  84. Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: a longitudinal MRI study.
    Neuroimage. 2005 Oct 1;27(4):934-46 PMID: 15979341
  85. Rates and risk factors for dementia and Alzheimer's disease: results from EURODEM pooled analyses. EURODEM Incidence Research Group and Work Groups. European Studies of Dementia.
    Neurology. 1999 Jan 1;52(1):78-84 PMID: 9921852
  86. An 18-year follow-up of overweight and risk of Alzheimer disease.
    Arch Intern Med. 2003 Jul 14;163(13):1524-8 PMID: 12860573
  87. Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam Study.
    Lancet. 1998 Jun 20;351(9119):1840-3 PMID: 9652667
  88. The effects of antihypertensive treatment on cognitive function: results from the HOPE study.
    J Am Geriatr Soc. 1996 Apr;44(4):411-5 PMID: 8636587
  89. Head injury and the risk of AD in the MIRAGE study.
    Neurology. 2000 Mar 28;54(6):1316-23 PMID: 10746604
  90. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein.
    Nature. 1998 Jan 22;391(6665):387-90 PMID: 9450754
  91. Metabolic syndrome and the risk of vascular dementia: the Italian Longitudinal Study on Ageing.
    J Neurol Neurosurg Psychiatry. 2010 Apr;81(4):433-40 PMID: 19965842
  92. Physical activity, diet, and risk of Alzheimer disease.
    JAMA. 2009 Aug 12;302(6):627-37 PMID: 19671904
  93. Apolipoprotein E genotypes and serum lipid levels in Alzheimer's disease and multi-infarct dementia.
    Int J Geriatr Psychiatry. 1997 Mar;12(3):359-62 PMID: 9152721
  94. Current and future uses of neuroimaging for cognitively impaired patients.
    Lancet Neurol. 2008 Feb;7(2):161-72 PMID: 18207114
  95. Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study.
    Dement Geriatr Cogn Disord. 2009;27(5):481-90 PMID: 19439966
  96. Cardiovascular risk factors and cognitive decline in middle-aged adults.
    Neurology. 2001 Jan 9;56(1):42-8 PMID: 11148234
  97. GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers.
    Neuron. 2007 Jun 7;54(5):713-20 PMID: 17553421
  98. A randomized trial of vitamin E supplementation and cognitive function in women.
    Arch Intern Med. 2006 Dec 11-25;166(22):2462-8 PMID: 17159011
  99. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease.
    Nat Med. 1996 Aug;2(8):864-70 PMID: 8705854
  100. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study.
    Arch Intern Med. 2002 Oct 14;162(18):2046-52 PMID: 12374512
  101. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort.
    Am J Epidemiol. 2001 Oct 1;154(7):635-41 PMID: 11581097
  102. Visual assessment of atrophy on magnetic resonance imaging in the diagnosis of pathologically confirmed young-onset dementias.
    Arch Neurol. 2005 Sep;62(9):1410-5 PMID: 16157748
  103. Longitudinal volumetric MRI change and rate of cognitive decline.
    Neurology. 2005 Aug 23;65(4):565-71 PMID: 16116117
  104. Cholesterol in Alzheimer's disease and tauopathy.
    Ann N Y Acad Sci. 2002 Nov;977:367-75 PMID: 12480774
  105. History of depression as a risk factor for dementia: an updated review.
    Aust N Z J Psychiatry. 2001 Dec;35(6):776-81 PMID: 11990888
  106. Head trauma as a risk factor for Alzheimer's disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group.
    Int J Epidemiol. 1991;20 Suppl 2:S28-35 PMID: 1833351
  107. Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study.
    Neurology. 2008 May 6;70(19):1664-71 PMID: 18401021
  108. Distribution and expression of picalm in Alzheimer disease.
    J Neuropathol Exp Neurol. 2010 Oct;69(10):1071-7 PMID: 20838239
  109. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome.
    JAMA. 2001 Nov 7;286(17):2120-7 PMID: 11694153
  110. Cdk5 is involved in NFT-like tauopathy induced by transient cerebral ischemia in female rats.
    Biochim Biophys Acta. 2007 Apr;1772(4):473-83 PMID: 17113760
  111. Fitness effects on the cognitive function of older adults: a meta-analytic study.
    Psychol Sci. 2003 Mar;14(2):125-30 PMID: 12661673
  112. Mediterranean diet and risk for Alzheimer's disease.
    Ann Neurol. 2006 Jun;59(6):912-21 PMID: 16622828
  113. Improvement of cognitive function by mental and/or individualized aerobic training in healthy elderly subjects.
    Int J Sports Med. 2002 Aug;23(6):415-21 PMID: 12215960
  114. Current and remote blood pressure and cognitive decline.
    JAMA. 1999 Feb 3;281(5):438-45 PMID: 9952204
  115. Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease.
    Nat Genet. 2009 Feb;41(2):192-8 PMID: 19136949
  116. Role of imaging techniques in the diagnosis of dementia.
    Br J Radiol. 2007 Dec;80 Spec No 2:S71-7 PMID: 18445747
  117. Amphiphysin heterodimers: potential role in clathrin-mediated endocytosis.
    Mol Biol Cell. 1997 Oct;8(10):2003-15 PMID: 9348539
  118. Beta-amyloid disrupted synaptic vesicle endocytosis in cultured hippocampal neurons.
    Neuroscience. 2007 Jun 15;147(1):60-70 PMID: 17499934
  119. Dietary fat intake and the risk of incident dementia in the Rotterdam Study.
    Ann Neurol. 1997 Nov;42(5):776-82 PMID: 9392577
  120. Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI.
    Neurology. 2007 Dec 11;69(24):2205-12 PMID: 18071141
  121. Diabetes mellitus and the risk of dementia: The Rotterdam Study.
    Neurology. 1999 Dec 10;53(9):1937-42 PMID: 10599761
  122. Meta-analysis of the association between variants in SORL1 and Alzheimer disease.
    Arch Neurol. 2011 Jan;68(1):99-106 PMID: 21220680
  123. Dietary antioxidants and the risk of ischemic stroke: the Rotterdam Study.
    Neurology. 2003 Nov 11;61(9):1273-5 PMID: 14610137
  124. Polyunsaturated fatty acids and reduced odds of MCI: the Mayo Clinic Study of Aging.
    J Alzheimers Dis. 2010;21(3):853-65 PMID: 20634591
  125. 15-year longitudinal study of blood pressure and dementia.
    Lancet. 1996 Apr 27;347(9009):1141-5 PMID: 8609748
  126. Peroxidase activity of cyclooxygenase-2 (COX-2) cross-links beta-amyloid (Abeta) and generates Abeta-COX-2 hetero-oligomers that are increased in Alzheimer's disease.
    J Biol Chem. 2004 Apr 9;279(15):14673-8 PMID: 14724276
  127. Antioxidant vitamin intake and risk of Alzheimer disease.
    Arch Neurol. 2003 Feb;60(2):203-8 PMID: 12580704
  128. Cyclin-dependent kinase 5 supports neuronal survival through phosphorylation of Bcl-2.
    J Neurosci. 2008 May 7;28(19):4872-7 PMID: 18463240
  129. Meta-analysis of CSF and MRI biomarkers for detecting preclinical Alzheimer's disease.
    Psychol Med. 2010 Jan;40(1):135-45 PMID: 19863841
  130. Genome-wide analysis of genetic loci associated with Alzheimer disease.
    JAMA. 2010 May 12;303(18):1832-40 PMID: 20460622
  131. Brain reserve hypothesis in dementia.
    J Alzheimers Dis. 2007 Aug;12(1):11-22 PMID: 17851191
  132. Exercise, cognition, and the aging brain.
    J Appl Physiol (1985). 2006 Oct;101(4):1237-42 PMID: 16778001
  133. The role of polyunsaturated fatty acids in restoring the aging neuronal membrane.
    Neurobiol Aging. 2002 Sep-Oct;23(5):843-53 PMID: 12392789
  134. 2010 Alzheimer's disease facts and figures.
    Alzheimers Dement. 2010 Mar;6(2):158-94 PMID: 20298981
  135. Influence of leisure activity on the incidence of Alzheimer's disease.
    Neurology. 2001 Dec 26;57(12):2236-42 PMID: 11756603
  136. Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury.
    Neurology. 2003 May 13;60(9):1457-61 PMID: 12743231
  137. Depressive symptoms, vascular disease, and mild cognitive impairment: findings from the Cardiovascular Health Study.
    Arch Gen Psychiatry. 2006 Mar;63(3):273-9 PMID: 16520432
  138. Impairment of long-term potentiation and spatial memory in leptin receptor-deficient rodents.
    Neuroscience. 2002;113(3):607-15 PMID: 12150780
  139. Synergistic effects of traumatic head injury and apolipoprotein-epsilon 4 in patients with Alzheimer's disease.
    Neurology. 1995 Mar;45(3 Pt 1):555-7 PMID: 7898715
  140. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease.
    Nature. 1996 Aug 22;382(6593):685-91 PMID: 8751438
  141. Differential CSF biomarker levels in APOE-epsilon4-positive and -negative patients with memory impairment.
    Dement Geriatr Cogn Disord. 2007;23(2):87-95 PMID: 17124416
  142. Cigarette smoking is a risk factor for Alzheimer's Disease: an analysis controlling for tobacco industry affiliation.
    J Alzheimers Dis. 2010;19(2):465-80 PMID: 20110594
  143. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.
    Neurology. 1984 Jul;34(7):939-44 PMID: 6610841
  144. No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease.
    Brain. 2007 Sep;130(Pt 9):2320-6 PMID: 17586559
  145. Serum or cerebrospinal fluid levels of glyceraldehyde-derived advanced glycation end products (AGEs) may be a promising biomarker for early detection of Alzheimer's disease.
    Med Hypotheses. 2005;64(6):1205-7 PMID: 15823718
  146. Depressed mood is not a risk factor for incident dementia in a community-based cohort.
    Am J Geriatr Psychiatry. 2009 Aug;17(8):653-63 PMID: 19634208
  147. Midlife dietary intake of antioxidants and risk of late-life incident dementia: the Honolulu-Asia Aging Study.
    Am J Epidemiol. 2004 May 15;159(10):959-67 PMID: 15128608
  148. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study.
    Prog Neuropsychopharmacol Biol Psychiatry. 2008 Aug 1;32(6):1538-44 PMID: 18573585
  149. An active and socially integrated lifestyle in late life might protect against dementia.
    Lancet Neurol. 2004 Jun;3(6):343-53 PMID: 15157849
  150. Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides.
    Neurodegener Dis. 2008;5(5):268-76 PMID: 18309230
  151. Vascular basis for brain degeneration: faltering controls and risk factors for dementia.
    Nutr Rev. 2010 Dec;68 Suppl 2:S74-87 PMID: 21091952
  152. Impact of antioxidants, zinc, and copper on cognition in the elderly: a randomized, controlled trial.
    Neurology. 2004 Nov 9;63(9):1705-7 PMID: 15534261
  153. Relation of corpus callosum and hippocampal size to age in nondemented adults with Down's syndrome.
    Am J Psychiatry. 2003 Oct;160(10):1870-8 PMID: 14514503
  154. Exercise, experience and the aging brain.
    Neurobiol Aging. 2002 Sep-Oct;23(5):941-55 PMID: 12392797
  155. Psychological and cognitive outcomes of a randomized trial of exercise among patients with chronic obstructive pulmonary disease.
    Health Psychol. 1998 May;17(3):232-40 PMID: 9619472
  156. Midlife activity predicts risk of dementia in older male twin pairs.
    Alzheimers Dement. 2008 Sep;4(5):324-31 PMID: 18790459
  157. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease.
    Arch Intern Med. 2003 May 12;163(9):1069-75 PMID: 12742805
  158. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial.
    Acta Neurol Scand Suppl. 2006;185:3-7 PMID: 16866904
  159. Apolipoprotein E epsilon4 association with dementia in a population-based study: The Framingham study.
    Neurology. 1996 Mar;46(3):673-7 PMID: 8618665
  160. Diabetes is related to cerebral infarction but not to AD pathology in older persons.
    Neurology. 2006 Dec 12;67(11):1960-5 PMID: 17159101
  161. The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics.
    Alzheimers Dement. 2008 Mar;4(2):145-53 PMID: 18631958
  162. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study.
    Diabetes. 2002 Apr;51(4):1256-62 PMID: 11916953
  163. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease.
    Nat Genet. 2007 Feb;39(2):168-77 PMID: 17220890
  164. Global prevalence of dementia: a Delphi consensus study.
    Lancet. 2005 Dec 17;366(9503):2112-7 PMID: 16360788
  165. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database.
    Nat Genet. 2007 Jan;39(1):17-23 PMID: 17192785
  166. Hippocampal atrophy as a quantitative trait in a genome-wide association study identifying novel susceptibility genes for Alzheimer's disease.
    PLoS One. 2009 Aug 07;4(8):e6501 PMID: 19668339
  167. Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease.
    Neurobiol Aging. 2011 Sep;32(9):1626-33 PMID: 19923038
  168. Effects of cognitive training interventions with older adults: a randomized controlled trial.
    JAMA. 2002 Nov 13;288(18):2271-81 PMID: 12425704
  169. Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk.
    Neurology. 2003 Nov 11;61(9):1185-90 PMID: 14610118
  170. Role of genes and environments for explaining Alzheimer disease.
    Arch Gen Psychiatry. 2006 Feb;63(2):168-74 PMID: 16461860
  171. Ascorbic acid protects against levodopa-induced neurotoxicity on a catecholamine-rich human neuroblastoma cell line.
    Mov Disord. 1993 Jul;8(3):278-84 PMID: 8341291
  172. Leisure activities and the risk of dementia in the elderly.
    N Engl J Med. 2003 Jun 19;348(25):2508-16 PMID: 12815136
  173. Apolipoprotein E type 4 allele and Alzheimer's disease: effect on age at onset and relative risk in different age groups.
    J Neurol. 1996 Jun;243(6):452-6 PMID: 8803817
  174. Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease.
    Brain Res Mol Brain Res. 1995 Oct;33(1):174-8 PMID: 8774959
  175. Risk of dementia among white and African American relatives of patients with Alzheimer disease.
    JAMA. 2002 Jan 16;287(3):329-36 PMID: 11790212
  176. Impact of APOE in mild cognitive impairment.
    Neurology. 2004 Nov 23;63(10):1898-901 PMID: 15557508
  177. Smoking and dementia in male British doctors: prospective study.
    BMJ. 2000 Apr 22;320(7242):1097-102 PMID: 10775216
  178. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial.
    J Hypertens. 2003 May;21(5):875-86 PMID: 12714861
  179. Adherence to a Mediterranean diet, cognitive decline, and risk of dementia.
    JAMA. 2009 Aug 12;302(6):638-48 PMID: 19671905
  180. In vivo mapping of amyloid toxicity in Alzheimer disease.
    Neurology. 2009 Apr 28;72(17):1504-11 PMID: 19398705
  181. Identification of snapin and three novel proteins (BLOS1, BLOS2, and BLOS3/reduced pigmentation) as subunits of biogenesis of lysosome-related organelles complex-1 (BLOC-1).
    J Biol Chem. 2004 Jul 2;279(27):28393-401 PMID: 15102850
  182. The metabolic syndrome and development of cognitive impairment among older women.
    Arch Neurol. 2009 Mar;66(3):324-8 PMID: 19273750
  183. Dysbindin (DTNBP1) and the biogenesis of lysosome-related organelles complex 1 (BLOC-1): main and epistatic gene effects are potential contributors to schizophrenia susceptibility.
    Biol Psychiatry. 2008 Jan 1;63(1):24-31 PMID: 17618940
  184. Documented head injury in early adulthood and risk of Alzheimer's disease and other dementias.
    Neurology. 2000 Oct 24;55(8):1158-66 PMID: 11071494
  185. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease.
    Nat Genet. 2009 Oct;41(10):1094-9 PMID: 19734903
  186. Head injury as a risk factor for Alzheimer's disease: the evidence 10 years on; a partial replication.
    J Neurol Neurosurg Psychiatry. 2003 Jul;74(7):857-62 PMID: 12810767
  187. Effect of memory impairment on training outcomes in ACTIVE.
    J Int Neuropsychol Soc. 2007 Nov;13(6):953-60 PMID: 17942013
  188. Precuneus atrophy in early-onset Alzheimer's disease: a morphometric structural MRI study.
    Neuroradiology. 2007 Dec;49(12):967-76 PMID: 17955233
  189. Elevated plasma amyloid beta-peptide 1-42 and onset of dementia in adults with Down syndrome.
    Neurosci Lett. 2001 Apr 6;301(3):199-203 PMID: 11257432
  190. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.
    Brain. 2006 Nov;129(Pt 11):2856-66 PMID: 16854944
  191. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study.
    Am J Geriatr Psychiatry. 2005 Nov;13(11):950-8 PMID: 16286438
  192. Mediterranean diet, Alzheimer disease, and vascular mediation.
    Arch Neurol. 2006 Dec;63(12):1709-17 PMID: 17030648
  193. Tobacco-related diseases. Is there a role for antioxidant micronutrient supplementation?
    Clin Chest Med. 2000 Mar;21(1):173-87, x PMID: 10763098
  194. Nonpharmacological cognitive interventions in aging and dementia.
    J Geriatr Psychiatry Neurol. 2007 Dec;20(4):239-49 PMID: 18004010
  195. The influence of smoking on the risk of Alzheimer's disease.
    Neurology. 1999 Apr 22;52(7):1408-12 PMID: 10227626
  196. A 32-year prospective study of change in body weight and incident dementia: the Honolulu-Asia Aging Study.
    Arch Neurol. 2005 Jan;62(1):55-60 PMID: 15642850
  197. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice.
    Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10837-42 PMID: 12119423
  198. Central obesity and increased risk of dementia more than three decades later.
    Neurology. 2008 Sep 30;71(14):1057-64 PMID: 18367704
  199. SORCS1 alters amyloid precursor protein processing and variants may increase Alzheimer's disease risk.
    Ann Neurol. 2011 Jan;69(1):47-64 PMID: 21280075
  200. No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer's disease.
    Brain. 2007 Oct;130(Pt 10):e82 PMID: 17615094
  201. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.
    Ann Neurol. 2004 Mar;55(3):306-19 PMID: 14991808
  202. Editorial: The prevalence and malignancy of Alzheimer disease. A major killer.
    Arch Neurol. 1976 Apr;33(4):217-8 PMID: 1259639
Article Info
Journal
Nature reviews. Neurology
Abbr.
Nat Rev Neurol
ISSN
1759-4766
Published
2011-03-00
Epub
2011-00-08
Pages
137-52
Language
English
Region
England
NLM ID
101500072
PMCID
PMC3339565
Subset
IM
Grants
NIA NIH HHS · P01 AG007232-20 · United States
NIA NIH HHS · K23 AG034550 · United States
NIA NIH HHS · P01 AG007232 · United States
NIA NIH HHS · R01 AG015473 · United States
NIA NIH HHS · R01 AG037212-03 · United States
Medical Research Council · G9901400 · United Kingdom
NIA NIH HHS · R37 AG015473-15 · United States
NIA NIH HHS · R01 AG015473-05 · United States
NIA NIH HHS · R37 AG015473 · United States
NIA NIH HHS · R01 AG037212 · United States
NIA NIH HHS · K23 AG034550-03 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com